| Verfasser: |
Cruijsen, M
van der Velden, W J F M
de Haan, A F J
Klein, S K
Hoogendoorn, M
Tromp, Y
de Valk, B
van Rees, B
de Boer, F
van der Spek, E
Pruijt, J
Verdonck, L F
Vellenga, E
Blijlevens, N
van de Loosdrecht, A A
Huls, G |
| Dokumenttyp: |
Artikel |
| Erscheinungsdatum: |
2020 |
| Reihe/Periodikum: |
Cruijsen , M , van der Velden , W J F M , de Haan , A F J , Klein , S K , Hoogendoorn , M , Tromp , Y , de Valk , B , van Rees , B , de Boer , F , van der Spek , E , Pruijt , J , Verdonck , L F , Vellenga , E , Blijlevens , N , van de Loosdrecht , A A & Huls , G 2020 , ' Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands : the OCEAN study ' , Leukemia & Lymphoma , vol. 61 , no. 11 , pp. 2752-2755 . https://doi.org/10.1080/10428194.2020.1775217 |
| Schlagwörter: |
RISK MYELODYSPLASTIC SYNDROMES
/ CANCER
/ MDS |
| Sprache: |
Englisch |
| Permalink: |
https://search.fid-benelux.de/Record/base-29191369 |
| Datenquelle: |
BASE;
Originalkatalog |
| Powered By: |
BASE |
| Link(s) :
|
https://hdl.handle.net/11370/6f589496-7d1d-40a0-a479-356e1e47405c |
